Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) priced an underwritten public offering of 9,859,155 common shares at $71.00 per share, raising approximately $700 million in gross proceeds before fees. The offering is expected to close on May 8, 2026 and includes a 30‑day option to sell 1,478,873 additional shares.
All shares are being sold by Cytokinetics; joint book‑running managers include Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies. The offering is made under a shelf registration effective February 27, 2025.
Positive
- Expected gross proceeds of approximately $700 million
- Large offering size: 9,859,155 shares priced at $71.00
- 30‑day overallotment option of 1,478,873 additional shares
- Underwritten by major banks: Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies
Negative
- Share issuance is dilutive: company selling 9,859,155 new shares
- Marketable supply may exert short‑term pressure on CYTK share price
- Closing is subject to customary conditions; offering may not complete
News Market Reaction – CYTK
In the May 7 session, CYTK declined 0.73%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 16 | Convertible notes offering | Negative | -4.4% | Upsized $650M 2031 convertible notes to refinance 2027 notes and fund launch. |
| May 28 | Equity offering closing | Negative | -0.7% | Closing of 9.8M-share common stock offering at $51 under existing shelf. |
| May 22 | Equity offering pricing | Negative | -17.3% | Pricing of 9.8M-share common stock deal at $51 with 30‑day option. |
| May 22 | Equity offering proposed | Negative | -17.3% | Announcement of proposed ~$500M common stock offering and 15% underwriter option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past financing and offering announcements for CYTK have consistently seen negative next-day moves, suggesting a recurring pattern of shareholder sensitivity to dilution and balance-sheet transactions.
Over the past two years, Cytokinetics has repeatedly accessed capital markets through equity and convertible offerings. Events on May 22–28, 2024 involved a sizable common stock raise around $51 per share, followed by a $650.0M convertible note deal on Sep 16, 2025. Each of these financing steps was followed by a negative price reaction, framing today’s upsized stock offering within a well-established funding pattern.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
base prospectus regulatory
preliminary prospectus supplement regulatory
final prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering. Mizuho is acting as lead co-manager for the offering and Citizens Capital Markets, Needham & Company, B. Riley Securities and H.C. Wainwright & Co. are acting as co-managers for the offering.
The securities described above are being offered by Cytokinetics pursuant to a shelf registration statement (including a base prospectus) filed on February 27, 2025 with the Securities and Exchange Commission (SEC), which has become automatically effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed, and a final prospectus supplement and accompanying prospectus relating to the offering will be filed, with the SEC and can be accessed for free on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone at 866-718-1649 or by email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ expectations regarding the completion of the offering. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, risks and uncertainties related to market and other conditions, and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Cytokinetics will be able to complete the public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the public offering, Cytokinetics and its business can be found under the heading “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025, which was filed on February 26, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed on May 5, 2026, and other filings with the SEC, and in the preliminary prospectus supplement related to the public offering, filed with the SEC on May 5, 2026. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
